The Second Affiliated Hospital of Wenzhou Medical University, Zhejiang, Zhejiang 325000
Wenzhou, Zhejiang, 325600, China
NCT Number: NCT07466511
Researchers hypothesized that Bifidobacterium breve Supplement could reduce the progression rate of idiopathic scoliosis in children and potentially prevent the occurrence of new cases of scoliosis.
Trial opening soon.
Get Notified6 year–15 year
All sexes
Interventional
Not applicable
Wenzhou, Zhejiang, 325600, China
Idiopathic scoliosis (IS) is a common pediatric disorder characterized by a spinal curvature exceeding 10 degrees that develops in the absence of obvious congenital or physiological defects. IS is highly prevalent during adolescence, afflicting 3-4% of children worldwide, yet the underlying causes remain poorly understood. Recent studies have indicated that children with idiopathic scoliosis have a disrupted gut microbiota, but there is currently no clinical data on the impact of any probiotic supplementation on scoliosis. Our unpublished data show that the abundance of probiotics such as Bifidobacterium breve in the intestines of children with idiopathic scoliosis is reduced, while the levels of multiple bile acids in the blood are elevated. Therefore, we hypothesize that Bifidobacterium breve supplementation can reduce the progression rate of idiopathic scoliosis in children and may have a potential role in preventing the onset of new cases of scoliosis in children.
This study is a single-blind, randomized controlled trial to investigate the effect of Bifidobacterium breve on the magnitude of idiopathic spinal curves. Eligible scoliosis children will be randomly assigned to one of two groups. The intervention group will receive oral supplementation of Bifidobacterium breve at 4.5x106 CFU daily for 6 months, along with a standardized gut microbiota-related health course for lifestyle correction (such as adjusting diet, moderate exercise, and reducing antibiotic abuse). The intervention group will be subject to regular phone follow-ups to inquire about probiotic intake and be encouraged to adhere to the regimen. The control group will receive the same health course but no probiotic supplementation, serving as an active control to account for the impact of lifestyle improvements. For all scoliosis children, routine follow-up visits will be scheduled every 6 months for at least 24 months to assess curve progression. Additionally, children who have not yet reached the scoliosis threshold at baseline will also be invited and randomly assigned to the same grouping scheme or simply followed up as observational subjects. All participating children, as part of a provincial health program in Zhejiang Province, will undergo annual scoliosis screening and clinical assessment.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Diagnosed with idiopathic scoliosis based on clinical evaluation and radiographic examination at the first clinic visit
Skeletally immature, defined as Risser sign 0 to 3
Major Cobb angle < 40 degrees at baseline
Written informed consent provided by the participant or legal guardian
Able and willing to comply with study procedures
Exclusion criteria
Use of antibiotics, probiotics, hormones, immunosuppressants, or other nutritional supplements known to affect gut microbiota within the past 3 months or during the study period without investigator approval
Known allergy, sensitivity, or intolerance to the investigational product or its ingredients
Current or prior significant gastrointestinal disease requiring medication, or history of gastrointestinal surgery
Severe gastrointestinal symptoms such as persistent heartburn or indigestion
Musculoskeletal, neurodevelopmental, syndromic, or other conditions that may account for the spinal deformity
History of spine surgery or major spinal injury
Spinal tumor or malignant disease involving the spine
Leg length discrepancy > 20 mm
Severe chronic diseases that could interfere with study participation or outcome assessment, including but not limited to diabetes, narcolepsy, or poorly controlled asthma
Severe obesity, defined as BMI z-score ≥ 3
Oral Bifidobacterium breve supplementation, 4.5 × 10^6 CFU daily for 6 months
A standardized education session delivered at baseline on diet optimization, appropriate exercise, and avoidance of unnecessary antibiotic use.
Time frame: Baseline and every 6 months up to 24 months
Major curve magnitude will be measured on standing full-spine radiographs using the standard Cobb method.
Time frame: Baseline and every 6 months up to 24 months
Trunk asymmetry will be assessed using a scoliometer to measure angle of trunk rotation.
Time frame: Baseline and every 6 months up to 24 months
Health-related quality of life will be assessed using the SRS-22 questionnaire, including pain, self-image, function, mental health, and treatment satisfaction.
Time frame: Baseline and Month 6
Gut microbial composition in stool samples will be assessed using metagenomic sequencing or polymerase chain reaction methods.
Time frame: Baseline and Month 6
Gastrointestinal symptoms and bowel movement frequency will be assessed through structured interview.
Time frame: Baseline and Month 6
Serum bile acid concentrations will be measured using blood samples collected from participants.
Contact information is provided by the study sponsor or research team.
Second Affiliated Hospital of Wenzhou Medical University
Other
Effect of Bifidobacterium Breve Supplementation on the Onset and Progression of Idiopathic Scoliosis: A Prospective, Single-Blind, Randomized Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07589023
Bone Diseases, Idiopathic Scoliosis
New York, United States
View Trial DetailsNCT07413588
Idiopathic Scoliosis
View Trial DetailsNCT07366996
Idiopathic Scoliosis
Gamasa, Egypt
View Trial DetailsNCT06908213
Idiopathic Scoliosis
Amiens, France
View Trial Details